Advaxis (ADXS) 10-Q 12 Mar 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jan. 31, 2018	Mar. 08, 2018
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	1,100,397
Document Type	10-Q
Document Period End Date	Jan. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		52,313,849
Trading Symbol	ADXS
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Current Assets:
Cash and cash equivalents	$ 25,932,403	$ 23,899,809
Restricted cash	977,000	587,000
Short-term investment securities	32,441,933	46,398,304
Income tax receivable		4,452,682
Deferred expenses	2,535,883	2,986,385
Prepaid expenses and other current assets	2,097,834	2,918,644
Total current assets	63,985,053	81,242,824
Property and equipment (net of accumulated depreciation)	7,923,612	7,111,081
Intangible assets (net of accumulated amortization)	4,974,995	4,856,775
Other assets	558,870	431,098
Total assets	77,442,530	93,641,778
Current liabilities:
Accounts payable	7,088,469	5,121,406
Accrued expenses	7,295,575	8,700,036
Deferred revenue	7,163,628	6,995,336
Other current liabilities	47,520	47,520
Total current liabilities	21,595,192	20,864,298
Deferred revenue	15,504,839	17,478,758
Other liabilities	1,071,694	1,038,555
Total liabilities	38,171,725	39,381,611
Commitments and contingencies - Note 9
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at January 31, 2018 and October 31, 2017. Liquidation preference of $0 at January 31, 2018 and October 31, 2017.
Common stock - $0.001 par value; 65,000,000 shares authorized, 42,283,221 shares issued and outstanding at January 31, 2018 and 41,206,538 shares issued and outstanding at October 31, 2017.	42,283	41,207
Additional paid-in capital	360,863,215	355,361,187
Accumulated deficit	(321,634,693)	(301,142,227)
Total stockholders' equity	39,270,805	54,260,167
Total liabilities and stockholders' equity	$ 77,442,530	$ 93,641,778

Condensed Balance Sheets (Unau3

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Series B Preferred stock, shares issued	0	0
Series B Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	42,283,221	41,206,538
Common stock, shares outstanding	42,283,221	41,206,538

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Income Statement [Abstract]
Revenue	$ 2,055,627	$ 3,790,842
Operating expenses:
Research and development expenses	17,070,266	13,648,554
General and administrative expenses	5,532,832	7,327,809
Total operating expenses	22,603,098	20,976,363
Loss from operations	(20,547,471)	(17,185,521)
Other income (expense):
Interest income, net	139,522	145,014
Net changes in fair value of derivative liabilities		9,504
Other expense	(34,517)
Net loss before income tax benefit	(20,442,466)	(17,031,003)
Income tax benefit	50,000	50,000
Net loss	$ (20,492,466)	$ (17,081,003)
Net loss per common share, basic and diluted	$ (0.49)	$ (0.43)
Weighted average number of common shares outstanding, basic and diluted	41,428,199	40,115,178

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
OPERATING ACTIVITIES
Net loss	$ (20,492,466)	$ (17,081,003)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	2,809,118	5,110,425
Gain on change in value of warrants and embedded derivative		(9,504)
Loss on disposal of property and equipment	27,361
Write-off of intangible assets	143,115
Depreciation expense	264,989	157,580
Amortization expense of intangible assets	92,525	74,410
Amortization of premium on held to maturity investments	2,545	44,005
Change in operating assets and liabilities:
Prepaid expenses and other current assets	1,396,312	(88,748)
Income tax receivable	4,452,682	2,549,862
Other assets	(127,772)	24,380
Accounts payable and accrued expenses	550,157	(1,454,011)
Deferred revenue	(1,805,627)	(3,540,842)
Other liabilities	33,139	48,355
Net cash used in operating activities	(12,653,922)	(14,165,091)
INVESTING ACTIVITIES
Restricted cash established with letter of credit agreement	(390,000)
Purchases of short-term investment securities	(12,487,174)	(46,525,169)
Sales of short-term investment securities	26,441,000	6,522,333
Purchase of property and equipment	(1,172,436)	(1,127,000)
Cost of intangible assets	(353,860)	(81,432)
Net cash provided by (used in) investing activities	12,037,530	(41,211,268)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock	2,658,749
Proceeds from employee stock purchase plan	9,482	67,923
Tax withholdings paid related to net share settlement of equity awards	(7,168)	(9,810)
Employee tax withholdings paid on equity awards	(208,892)	(204,614)
Tax shares sold to pay for employee tax withholdings on equity awards	196,815	338,486
Net cash provided by financing activities	2,648,986	191,985
Net increase (decrease) in cash and cash equivalents	2,032,594	(55,184,374)
Cash and cash equivalents at beginning of period	23,899,809	112,750,980
Cash and cash equivalents at end of period	25,932,403	57,566,606
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes	50,000	50,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Accounts payable and accrued expenses settled with common stock		75,000
Property and equipment included in accounts payable and accrued expenses	$ 57,445	$ 115,637

Nature of Operations

Nature of Operations	3 Months Ended
	Jan. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. NATURE OF OPERATIONS Advaxis, Inc. (“Advaxis” or the “Company”) is a late-stage biotechnology Company focused on the discovery, development and commercialization of proprietary Lm Listeria monocytogenes Lm Lm Lm Lm Advaxis is focused on four franchises in various stages of clinical and pre-clinical development, which they believe will provide the greatest opportunity to have a significant impact on patients and their families: ● Human Papilloma Virus (“HPV”)-associated cancers ● Individualized neoantigen therapy ● Disease focused hotspot / cancer antigen therapies ● Prostate cancer All four clinical franchises are anchored in the Company’s Lm Lm Lm Liquidity and Financial Condition The Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses. These losses are expected to continue for an extended period of time. Our major sources of cash have been proceeds from various public and private offerings of our common stock, option and warrant exercises, and interest income. From October 2013 through February 2018, we raised approximately $245.2 million in gross proceeds from various public and private offerings of our common stock. As of January 31, 2018, the Company had approximately $59.4 million in cash, restricted cash, cash equivalents and short-term investment securities on its balance sheet. The Company has plans to continue to be disciplined in regard to its utilization of its capital and anticipates its cash burn will decrease from fiscal 2017. This decrease will largely be due to several one-time items in fiscal 2017 related to the preparation of our Marketing Authorization Application (“MAA”) filing in Europe of axalimogene filolisbac and other one-time costs that the Company does not anticipate to recur. Additionally, during February 2018 the Company entered into an underwritten public offering of its Common Stock, raising gross proceeds of $20 million. We believe our current cash position as of January 31, 2018 along with the net proceeds received from the Company’s underwritten public offering that closed on February 26, 2018 is sufficient to fund our business plan approximately into second calendar quarter of 2019. The actual amount of cash that we will need to operate is subject to many factors. The Company recognizes it may need to raise additional capital in order to continue to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	3 Months Ended
	Jan. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the SEC with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited condensed balance sheet as of October 31, 2017 has been derived from the Company’s October 31, 2017 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), the fair value of investments, the fair value of options and warrants, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company for the year ended October 31, 2017 and notes thereto contained in the Company’s annual report on Form 10-K for the year ended October 31, 2017, as filed with the SEC on December 21, 2017. Concentration of Credit Risk The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $25.6 million is subject to credit risk at January 31, 2018. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk. Restricted Cash and Letters of Credit During July 2017 and January 2018, the Company established two letters of credit with a financial institution as security for the purchase of custom equipment and as security for application fees associated with the Company’s MAA in Europe. The letters of credit are collateralized by cash which is unavailable for withdrawal or for usage for general obligations. No amount is outstanding under either letter of credit as of January 31, 2018. Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share. As of January 31, 2018 2017 Warrants 3,092,395 3,110,575 Stock Options 4,442,558 3,897,558 Restricted Stock Units 1,257,526 1,111,059 Total 8,792,479 8,119,192 Recent Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (“ASU 2016-08”); ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”); ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”); and ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers (“ASU 2016-20”). The Company must adopt ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20 with ASU 2014-09 (collectively, the “new revenue standards”). The new revenue standards may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. We are currently evaluating which transition approach we will utilize and the impact of adopting this accounting standard on our unaudited condensed financial statements. This update will be effective for the Company beginning in the first quarter of 2019. In February 2016, the FASB issued ASU 2016-02, “Leases (“Topic 842”) (“ASU 2016-02”). The standard amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of 2019. Early adoption of ASU 2016-02 is permitted. The new leases standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Short-Term Investment Securitie

Short-Term Investment Securities	3 Months Ended
	Jan. 31, 2018
Schedule of Investments [Abstract]
Short-Term Investment Securities	3. SHORT-TERM INVESTMENT SECURITIES The following table summarizes the Company’s investment securities at amortized cost as of January 31, 2018 and October 31, 2017: January 31, 2018 Amortized cost, as adjusted Gross unrealized holding gains Gross unrealized holding losses Estimated fair value Short-term investments: Certificates of Deposit $ 2,449,989 $ - $ - $ 2,449,989 U.S Treasury Notes 29,991,944 - 17,809 29,974,135 Total short-term investment securities $ 32,441,933 $ - $ 17,809 $ 32,424,124 October 31, 2017 Amortized cost, as adjusted Gross unrealized holding gains Gross unrealized holding losses Estimated fair value Short-term investments: Certificates of Deposit $ 11,391,147 $ - $ - $ 11,391,147 Domestic Governmental Agency Loans 499,957 - 162 499,795 U.S Treasury Notes 34,507,200 - 25,351 34,481,849 Total short-term investment securities $ 46,398,304 $ - $ 25,513 $ 46,372,791 All the Company’s short-term investment securities mature within the next 12 months.

Property and Equipment

Property and Equipment	3 Months Ended
	Jan. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	4. PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: January 31, 2018 October 31, 2017 Leasehold improvements $ 2,248,751 $ 2,167,990 Laboratory equipment 5,218,172 4,143,106 Furniture and fixtures 728,725 728,725 Computer equipment 394,523 394,523 Construction in progress 805,014 883,322 Total property and equipment 9,395,185 8,317,666 Accumulated depreciation and amortization (1,471,573 ) (1,206,585 ) Net property and equipment $ 7,923,612 $ 7,111,081 Depreciation expense for the three months ended January 31, 2018 and 2017 was $264,989 and $157,580 respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Jan. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. INTANGIBLE ASSETS Intangible assets, net consist of the following: January 31, 2018 October 31, 2017 Patents $ 5,879,973 $ 5,727,298 Licenses 776,992 776,992 Software 117,196 108,604 Total intangibles 6,774,161 6,612,894 Accumulated amortization (1,799,166 ) (1,756,119 ) Intangible assets $ 4,974,995 $ 4,856,775 The expirations of the existing patents range from 2018 to 2038 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of $143,115 and $0 were abandoned and were charged to research and development expenses in the Statement of Operations for the three months ended January 31, 2018 and 2017, respectively. Amortization expense for intangible assets aggregated $92,525 and $74,410 for the three months ended January 31, 2018 and 2017, respectively. At January 31, 2018, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows: Year ended October 31, 2018 (Remaining) $ 286,733 2019 379,911 2020 363,056 2021 343,246 2022 343,246 Thereafter 3,258,803 Total $ 4,974,995

Accrued Expenses

Accrued Expenses	3 Months Ended
	Jan. 31, 2018
Payables and Accruals [Abstract]
Accrued Expenses	6. ACCRUED EXPENSES: The following table represents the major components of accrued expenses: January 31, 2018 October 31, 2017 Salaries and other compensation $ 3,576,946 $ 2,652,583 Vendors 972,018 2,811,956 Professional fees 2,746,611 3,235,497 Total accrued expenses $ 7,295,575 $ 8,700,036

Warrants

Warrants	3 Months Ended
	Jan. 31, 2018
Warrants
Warrants	7. WARRANTS At January 31, 2018 and October 31, 2017, the Company had 3,092,395 warrants outstanding at a weighted average exercise price of $5.00 and a weighted average remaining contractual life of .92 and .67 years, respectively. At January 31, 2018 and October 31, 2017, all of the Company’s outstanding warrants were classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the stockholders’ equity section of the balance sheet. The Company’s equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

Share Based Compensation

Share Based Compensation	3 Months Ended
	Jan. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share Based Compensation	8. SHARE BASED COMPENSATION The following table summarizes share-based compensation expense included in the Statement of Operations: Three Months Ended January 31, 2018 2017 Research and development $ 1,272,997 $ 1,222,483 General and administrative 1,536,121 3,887,942 Total $ 2,809,118 $ 5,110,425 Restricted Stock Units (RSUs) A summary of the Company’s RSU activity and related information for the three months ended January 31, 2018 is as follows: Number of RSUs Weighted-Average Grant Date Fair Value Balance at October 31, 2017: 1,363,119 $ 8.54 Granted 84,000 3.19 Vested (186,970 ) 8.29 Cancelled (2,623 ) 7.94 Balance at January 31, 2018 1,257,526 $ 8.22 As of January 31, 2018, there was approximately $7,988,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.80 years. As of January 31, 2018, the aggregate intrinsic value of non-vested RSUs was approximately $3,722,000. Employee Stock Awards Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 197,167 shares (195,046 shares on a net basis after employee taxes) and 93,976 shares (92,731 shares on a net basis after employee taxes) during the three months ended January 31, 2018 and 2017 respectively. Total stock compensation expense associated with these awards for the three months ended January 31, 2018 and 2017 was $1,354,185 and $1,356,639, respectively. Director Stock Awards During the three months ended January 31, 2018 and 2017, total stock compensation expense to the Directors for amortization of unvested awards was $101,628 and $101,628, respectively. Stock Options A summary of changes in the stock option plan for the three months ended January 31, 2018 is as follows: Number of Weighted-Average Options Exercise Price Outstanding at October 31, 2017: 3,893,558 $ 12.51 Granted 761,685 3.11 Canceled or Expired (212,685 ) 12.11 Outstanding at January 31, 2018 4,442,558 10.91 Vested and Exercisable at January 31, 2018 3,150,667 $ 12.80 Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended January 31, 2018 and 2017 was $1,398,304 and $3,183,458, respectively. During the three months ended January 31, 2018, 761,685 options were granted with a total grant date fair value of $1,856,699. During the three months ended January 31, 2017, 556,952 options were granted with a total grant date fair value of $3,542,215. As of January 31, 2018, there was approximately $4,877,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.53 years. As of January 31, 2018, the aggregate intrinsic value of vested and exercisable options was $0. In determining the fair value of the stock options granted during the three months ended January 31, 2018 and 2017, the Company used the following inputs in its BSM: Three Months Ended January 31, 2018 2017 Expected Term 5.50-6.50 years 5.50-6.50 years Expected Volatility 95.11-100.34 % 107.07-110.93 % Expected Dividends 0 % 0 % Risk Free Interest Rate 2.00-2.66 % 1.26-1.58 % Shares Issued to Consultants During the three months ended January 31, 2017, 32,500 shares of Common Stock valued at $313,600 were issued to consultants for services, of which $75,000 represented shares issued for amounts previously accrued. The Company recorded a liability on its balance sheet for $230,100 for shares earned pursuant to consulting agreements but not delivered. The common stock share values were based on the dates the shares vested.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jan. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCIES Legal Proceedings Bono On August 20, 2015, a derivative complaint was filed by a purported Company stockholder in the United States District Court for the District of New Jersey styled David Bono v. O’Connor, et al., Case No. 3:15-CV-006326-FLW-DEA (D.N.J. Aug. 20, 2015) (the “Bono Action”). The complaint is based on general allegations related to certain stock options granted to the individual defendants and generally alleges counts for breaches of fiduciary duty and unjust enrichment. The complaint also alleges additional claims for violation of Section 14(a) of the Securities Exchange Act of 1934 and for waste of corporate assets. The complaint seeks damages and costs of an unspecified amount, disgorgement of compensation obtained by the individual defendants, and injunctive relief. Defendants filed a motion to dismiss the Bono Action. On May 23, 2016, the Court issued an opinion and order granting in part and denying in part defendants’ motion to dismiss. On October 5, 2016, the Court denied plaintiff’s motion for reconsideration of its May 23 order. On April 13, 2017, the parties advised the Court that they had reached a tentative agreement in principle to settle the action, subject to negotiating an award of attorneys’ fees and expenses to plaintiff’s counsel and a stipulation of settlement, and, ultimately, Court approval. The parties subsequently executed the stipulation of settlement on October 2, 2017. The Court entered an order preliminarily approving the settlement on November 7, 2017. The final fairness hearing was held January 29, 2018, and the Order and Final Judgment approving the settlement and dismissing the action with prejudice was entered on January 29, 2018. Corporate Office & Manufacturing Facility Lease The Company leases its corporate office and manufacturing facility under an operating lease expiring in November 2025. Future minimum payments under the Company’s operating leases are as follows: Year ended October 31, 2018 (remaining) $ 785,514 2019 1,107,385 2020 1,232,907 2021 1,317,640 2022 1,368,819 Thereafter 4,378,521 Total $ 10,190,786

Income Taxes

Income Taxes	3 Months Ended
	Jan. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act significantly revises U.S. corporate income taxation by, among other things, lowering the U.S. corporate income tax rate from 35.0 % to 21.0% effective January 1, 2018. The decrease in the U.S. federal corporate tax rate from 35.0% to 21.0% will result in a blended statutory tax rate of 23.2% for the fiscal year ending October 31, 2018. The Company does not anticipate any impact to tax expense due to the full valuation allowance of the Company and believes that the most significant impact on its financial statements will be reduction of approximately $32.7 million for the deferred tax assets related to net operating losses and other assets. Such reduction is offset by changes to the Company’s valuation allowance. In December 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin 118, which allows a measurement period, not to exceed one year, to finalize the accounting for the income tax impacts of the Tax Act. Until the accounting for the income tax impacts of the Tax Act is complete, the reported amounts are based on reasonable estimates, are disclosed as provisional and reflect any adjustments in subsequent periods as they refine their estimates or complete their accounting of such tax effects.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jan. 31, 2018
Equity [Abstract]
Stockholders' Equity	11. STOCKHOLDERS’ EQUITY During the three months ended January 31, 2018, the Company sold 881,629 shares of its Common Stock at-the-market transactions resulting in net proceeds of approximately $2,659,000.

Subsequent Events

Subsequent Events	3 Months Ended
	Jan. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	12. SUBSEQUENT EVENTS During February 2018, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Guggenheim Securities, LLC (the “Underwriters”). Pursuant to the Underwriting Agreement, the Company sold to the Underwriters, and the Underwriters purchased for resale to the public, in a firm commitment underwritten public offering, 10,000,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $2.00 per share, less underwriting discounts and commissions. The net proceeds to the Company from the transaction was $18.8 million before expenses. In addition, pursuant to the Underwriting Agreement, the Company has granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 807,697 shares of Common Stock (the “Optional Shares” and, together with the Shares, the “Offered Shares”). The sale of the Offered Shares was registered pursuant to a Registration Statement (No. 333-216008) on Form S-3, as amended, which was filed by the Company with the Securities and Exchange Commission on March 17, 2017, and declared effective on March 20, 2017.

Summary of Significant Accoun18

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	3 Months Ended
	Jan. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation/Estimates	Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the SEC with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited condensed balance sheet as of October 31, 2017 has been derived from the Company’s October 31, 2017 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), the fair value of investments, the fair value of options and warrants, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company for the year ended October 31, 2017 and notes thereto contained in the Company’s annual report on Form 10-K for the year ended October 31, 2017, as filed with the SEC on December 21, 2017.
Concentration of Credit Risk	Concentration of Credit Risk The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $25.6 million is subject to credit risk at January 31, 2018. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
Restricted Cash and Letters of Credit	Restricted Cash and Letters of Credit During July 2017 and January 2018, the Company established two letters of credit with a financial institution as security for the purchase of custom equipment and as security for application fees associated with the Company’s MAA in Europe. The letters of credit are collateralized by cash which is unavailable for withdrawal or for usage for general obligations. No amount is outstanding under either letter of credit as of January 31, 2018.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share. As of January 31, 2018 2017 Warrants 3,092,395 3,110,575 Stock Options 4,442,558 3,897,558 Restricted Stock Units 1,257,526 1,111,059 Total 8,792,479 8,119,192
Recent Accounting Standards	Recent Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (“ASU 2016-08”); ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”); ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”); and ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers (“ASU 2016-20”). The Company must adopt ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20 with ASU 2014-09 (collectively, the “new revenue standards”). The new revenue standards may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. We are currently evaluating which transition approach we will utilize and the impact of adopting this accounting standard on our unaudited condensed financial statements. This update will be effective for the Company beginning in the first quarter of 2019. In February 2016, the FASB issued ASU 2016-02, “Leases (“Topic 842”) (“ASU 2016-02”). The standard amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of 2019. Early adoption of ASU 2016-02 is permitted. The new leases standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Summary of Significant Accoun19

Summary of Significant Accounting Policies and Basis of Presentation (Tables)	3 Months Ended
	Jan. 31, 2018
Accounting Policies [Abstract]
Schedule of Common Stock Excluded from Diluted Net Loss Per Share	The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share. As of January 31, 2018 2017 Warrants 3,092,395 3,110,575 Stock Options 4,442,558 3,897,558 Restricted Stock Units 1,257,526 1,111,059 Total 8,792,479 8,119,192

Short-Term Investment Securit20

Short-Term Investment Securities (Tables)	3 Months Ended
	Jan. 31, 2018
Schedule of Investments [Abstract]
Schedule of Investment Securities at Amortized	The following table summarizes the Company’s investment securities at amortized cost as of January 31, 2018 and October 31, 2017: January 31, 2018 Amortized cost, as adjusted Gross unrealized holding gains Gross unrealized holding losses Estimated fair value Short-term investments: Certificates of Deposit $ 2,449,989 $ - $ - $ 2,449,989 U.S Treasury Notes 29,991,944 - 17,809 29,974,135 Total short-term investment securities $ 32,441,933 $ - $ 17,809 $ 32,424,124 October 31, 2017 Amortized cost, as adjusted Gross unrealized holding gains Gross unrealized holding losses Estimated fair value Short-term investments: Certificates of Deposit $ 11,391,147 $ - $ - $ 11,391,147 Domestic Governmental Agency Loans 499,957 - 162 499,795 U.S Treasury Notes 34,507,200 - 25,351 34,481,849 Total short-term investment securities $ 46,398,304 $ - $ 25,513 $ 46,372,791

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Jan. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following: January 31, 2018 October 31, 2017 Leasehold improvements $ 2,248,751 $ 2,167,990 Laboratory equipment 5,218,172 4,143,106 Furniture and fixtures 728,725 728,725 Computer equipment 394,523 394,523 Construction in progress 805,014 883,322 Total property and equipment 9,395,185 8,317,666 Accumulated depreciation and amortization (1,471,573 ) (1,206,585 ) Net property and equipment $ 7,923,612 $ 7,111,081

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Jan. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets, net consist of the following: January 31, 2018 October 31, 2017 Patents $ 5,879,973 $ 5,727,298 Licenses 776,992 776,992 Software 117,196 108,604 Total intangibles 6,774,161 6,612,894 Accumulated amortization (1,799,166 ) (1,756,119 ) Intangible assets $ 4,974,995 $ 4,856,775
Schedule of Amortization Expense	At January 31, 2018, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows: Year ended October 31, 2018 (Remaining) $ 286,733 2019 379,911 2020 363,056 2021 343,246 2022 343,246 Thereafter 3,258,803 Total $ 4,974,995

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Jan. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	The following table represents the major components of accrued expenses: January 31, 2018 October 31, 2017 Salaries and other compensation $ 3,576,946 $ 2,652,583 Vendors 972,018 2,811,956 Professional fees 2,746,611 3,235,497 Total accrued expenses $ 7,295,575 $ 8,700,036

Share Based Compensation (Table

Share Based Compensation (Tables)	3 Months Ended
	Jan. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Share-based Compensation Expense	The following table summarizes share-based compensation expense included in the Statement of Operations: Three Months Ended January 31, 2018 2017 Research and development $ 1,272,997 $ 1,222,483 General and administrative 1,536,121 3,887,942 Total $ 2,809,118 $ 5,110,425
Summary of RSU Activity and Related Information	A summary of the Company’s RSU activity and related information for the three months ended January 31, 2018 is as follows: Number of RSUs Weighted-Average Grant Date Fair Value Balance at October 31, 2017: 1,363,119 $ 8.54 Granted 84,000 3.19 Vested (186,970 ) 8.29 Cancelled (2,623 ) 7.94 Balance at January 31, 2018 1,257,526 $ 8.22
Summary of Changes in Stock Option Plan	A summary of changes in the stock option plan for the three months ended January 31, 2018 is as follows: Number of Weighted-Average Options Exercise Price Outstanding at October 31, 2017: 3,893,558 $ 12.51 Granted 761,685 3.11 Canceled or Expired (212,685 ) 12.11 Outstanding at January 31, 2018 4,442,558 10.91 Vested and Exercisable at January 31, 2018 3,150,667 $ 12.80
Summary of Fair Value of Stock Options Granted of BSM	In determining the fair value of the stock options granted during the three months ended January 31, 2018 and 2017, the Company used the following inputs in its BSM: Three Months Ended January 31, 2018 2017 Expected Term 5.50-6.50 years 5.50-6.50 years Expected Volatility 95.11-100.34 % 107.07-110.93 % Expected Dividends 0 % 0 % Risk Free Interest Rate 2.00-2.66 % 1.26-1.58 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Jan. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Summary of Future Minimum Payments of Operating Leases	Future minimum payments under the Company’s operating leases are as follows: Year ended October 31, 2018 (remaining) $ 785,514 2019 1,107,385 2020 1,232,907 2021 1,317,640 2022 1,368,819 Thereafter 4,378,521 Total $ 10,190,786

Nature of Operations (Details N

Nature of Operations (Details Narrative)	3 Months Ended
	Jan. 31, 2018USD ($)
Cash, restricted cash, cash equivalents and investments	$ 59,400,000
October 2013 Through February 2018 [Member]
Proceeds from public offering	245,200,000
February 2018 [Member]
Proceeds from public offering	$ 20,000,000

Summary of Significant Accoun27

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative)	3 Months Ended
	Jan. 31, 2018USD ($)
Accounting Policies [Abstract]
Concentration of credit risk	$ 25,600,000

Summary of Significant Accoun28

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Common Stock Excluded from Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Number of common stock excluded from diluted net loss per share	8,792,479	8,119,192
Warrants [Member]
Number of common stock excluded from diluted net loss per share	3,092,395	3,110,575
Stock Options [Member]
Number of common stock excluded from diluted net loss per share	4,442,558	3,897,558
Restricted Stock Units (RSUs) [Member]
Number of common stock excluded from diluted net loss per share	1,257,526	1,111,059

Short-Term Investment Securit29

Short-Term Investment Securities (Details Narrative)	3 Months Ended
	Jan. 31, 2018
Schedule of Investments [Abstract]
Investments maturity description	All the Company’s investments mature within the next 12 months.

Short-Term Investment Securit30

Short-Term Investment Securities - Schedule of Investment Securities at Amortized (Details) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Amortized cost, as adjusted	$ 32,441,933	$ 46,398,304
Gross unrealized holding gains
Gross unrealized holding losses	17,809	25,513
Estimated fair value	32,424,124	46,372,791
Certificates of Deposit [Member]
Amortized cost, as adjusted	2,449,989	11,391,147
Gross unrealized holding gains
Gross unrealized holding losses
Estimated fair value	2,449,989	11,391,147
U.S Treasury Notes [Member]
Amortized cost, as adjusted	29,991,944	34,507,200
Gross unrealized holding gains
Gross unrealized holding losses	17,809	25,351
Estimated fair value	$ 29,974,135	34,481,849
Domestic Governmental Agency Loans [Member]
Amortized cost, as adjusted		499,957
Gross unrealized holding gains
Gross unrealized holding losses		162
Estimated fair value		$ 499,795

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 264,989	$ 157,580

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,248,751	$ 2,167,990
Laboratory equipment	5,218,172	4,143,106
Furniture and fixtures	728,725	728,725
Computer equipment	394,523	394,523
Construction in progress	805,014	883,322
Total property and equipment	9,395,185	8,317,666
Accumulated depreciation and amortization	(1,471,573)	(1,206,585)
Net property and equipment	$ 7,923,612	$ 7,111,081

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived patents expirations year	The expirations of the existing patents range from 2018 to 2038
Book value patent applications, net	$ 143,115	$ 0
Amortization expense of intangible assets	$ 92,525	$ 74,410

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 5,879,973	$ 5,727,298
License	776,992	776,992
Software	117,196	108,604
Total intangibles	6,774,161	6,612,894
Accumulated amortization	(1,799,166)	(1,756,119)
Net intangible assets	$ 4,974,995	$ 4,856,775

Intangible Assets - Schedule of

Intangible Assets - Schedule of Amortization Expense (Details)	Jan. 31, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2018 (Remaining)	$ 286,733
2,019	379,911
2,020	363,056
2,021	343,246
2,022	343,246
Thereafter	3,258,803
Total	$ 4,974,995

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Payables and Accruals [Abstract]
Salaries and other compensation	$ 3,576,946	$ 2,652,583
Vendors	972,018	2,811,956
Professional fees	2,746,611	3,235,497
Total accrued expenses	$ 7,295,575	$ 8,700,036

Warrants (Details Narrative)

Warrants (Details Narrative) - $ / shares	3 Months Ended	12 Months Ended
	Jan. 31, 2018	Oct. 31, 2017
Warrants outstanding	3,092,395	3,092,395
Exercise price of warrants	$ 5	$ 5
Warrants [Member]
Weighted average remaining contractual life	11 months 1 day	8 months 2 days

Share Based Compensation (Detai

Share Based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Unrecognized compensation cost related to non-vested stock option awards	$ 4,877,000
Compensation cost related to outstanding stock options	$ 1,398,904	$ 3,183,458
Number of options, granted	761,685	556,952
Fair value of option granted	$ 1,856,699	$ 3,542,215
Weighted average vesting period	1 year 6 months 10 days
Aggregate intrinsic value of vested and exercisable	$ 0
Accounts payable and accrued expenses settled with common stock		75,000
Directors [Member]
Stock compensation expense	101,628	$ 101,628
Consultants [Member]
Stock issued during period for services		32,500
Stock issued during period value for services		$ 313,600
Accounts payable and accrued expenses settled with common stock		75,000
Consultants [Member]
Recorded a liability		$ 230,100
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards	$ 7,988,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period	1 year 9 months 18 days
Options outstanding, intrinsic value	$ 3,722,000
Number of options, granted	84,000
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	197,167	93,976
Share-based compensation, shares on net basis after employee payroll taxes	195,046	92,731
Stock compensation expense	$ 1,354,185	$ 1,356,639

Share Based Compensation - Summ

Share Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Share-based compensation expense	$ 2,809,118	$ 5,110,425
Research and Development [Member]
Share-based compensation expense	1,272,997	1,222,483
General and Administrative [Member]
Share-based compensation expense	$ 1,536,121	$ 3,887,942

Share Based Compensation - Su40

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - $ / shares	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Beginning Balance	3,893,558
Number of RSUs Granted	761,685	556,952
Number of RSUs Cancelled	(212,685)
Ending Balance	4,442,558
Weighted-Average Exercise Price, Outstanding, Beginning	$ 12.51
Weighted-Average Exercise Price, Granted	3.11
Weighted-Average Exercise Price, Cancelled	12.11
Weighted-Average Exercise Price, Outstanding, Ending	$ 10.91
Restricted Stock Units (RSUs) [Member]
Beginning Balance	1,363,119
Number of RSUs Granted	84,000
Number of RSUs Vested	(186,970)
Number of RSUs Cancelled	(2,623)
Ending Balance	1,257,526
Weighted-Average Exercise Price, Outstanding, Beginning	$ 8.54
Weighted-Average Exercise Price, Granted	3.19
Weighted-Average Exercise Price, Vested	8.29
Weighted-Average Exercise Price, Cancelled	7.94
Weighted-Average Exercise Price, Outstanding, Ending	$ 8.22

Share Based Compensation - Su41

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) - $ / shares	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning Balance	3,893,558
Number of Options, Granted	761,685	556,952
Number of Options, Expired	(212,685)
Ending Balance	4,442,558
Number of Options, Vested and Exercisable	3,150,667
Weighted-Average Exercise Price, Outstanding, Beginning	$ 12.51
Weighted-Average Exercise Price, Granted	3.11
Weighted-Average Exercise Price, Expired	12.11
Weighted-Average Exercise Price, Outstanding, Ending	10.91
Weighted-Average Exercise Price, Vested and Exercisable	$ 12.80

Share Based Compensation - Su42

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Expected Volatility, Minimum	95.11%	107.07%
Expected Volatility, Maximum	100.34%	110.93%
Expected Dividends	0.00%	0.00%
Risk Free Interest Rate, Minimum	2.00%	1.26%
Risk Free Interest Rate, Maximum	2.66%	1.58%
Minimum [Member]
Expected Term	5 years 6 months	5 years 6 months
Maximum [Member]
Expected Term	6 years 6 months	6 years 6 months

Commitments and Contingencies43

Commitments and Contingencies (Details Narrative)	3 Months Ended
	Jan. 31, 2018
Corporate Office & Manufacturing Facility Lease [Member]
Agreement expiration date	Nov. 30, 2025

Commitments and Contingencies -

Commitments and Contingencies - Summary of Future Minimum Payments of Operating Leases (Details)	Jan. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018 (remaining)	$ 785,514
2,019	1,107,385
2,020	1,232,907
2,021	1,317,640
2,022	1,368,819
Thereafter	4,378,521
Total	$ 10,190,786

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 22, 2017	Jan. 31, 2018
Federal tax rate, percentage	35.00%
Percentage of lower tax rate	21.00%
Net operating loss carry-forward		$ 32,700,000
October 31, 2018 [Member]
Federal tax rate, percentage	35.00%
Income tax effective tax rate	23.20%
October 31, 2018 [Member] | Reduced Federal Tax Rate[Member]
Federal tax rate, percentage	21.00%

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Equity [Abstract]
Number of common stock shares sold	881,629
Proceeds from sale of common stock	$ 2,658,749

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 28, 2018	Jan. 31, 2018	Jan. 31, 2017	Oct. 31, 2017
Sale of stock transaction during period		881,629
Common stock, par value		$ 0.001		$ 0.001
Number of options, granted		761,685	556,952
Subsequent Event [Member] | Underwriting Agreement [Member]
Sale of stock transaction during period	10,000,000
Common stock, par value	$ 0.001
Sale of stock transaction during period, value	$ 18,800,000
Sale of stock price per share	$ 2
Number of options, granted	807,697